Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: TSE:VRX
- CUSIP: N/A
- Web: www.valeant.com/
Capitalization:- Market Cap: C$5.89 billion
- Outstanding Shares: 348,521,000
Average Prices:- 50 Day Moving Avg: C$17.69
- 200 Day Moving Avg: C$17.15
- 52 Week Range: C$11.20 - C$36.65
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: -0.33
Sales & Book Value:- Annual Revenue: C$9.22 billion
- Price / Sales: 0.64
- Book Value: C$11.28 per share
- Price / Book: 1.50
Profitability:- EBIDTA: C$3.75 billion
- Net Margins: -1.66%
- Return on Equity: -3.90%
- Return on Assets: -0.35%
Misc:- Average Volume: 1.42 million shs.
- Short Ratio: 11.1
Frequently Asked Questions for Valeant Pharmaceuticals Intl (TSE:VRX)
What is Valeant Pharmaceuticals Intl's stock symbol?
Valeant Pharmaceuticals Intl trades on the Tornton Stock Exchange (TSX) under the ticker symbol "VRX."
When will Valeant Pharmaceuticals Intl make its next earnings announcement?
Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2017?
5 brokerages have issued 1 year price objectives for Valeant Pharmaceuticals Intl's stock. Their forecasts range from C$19.00 to C$26.00. On average, they anticipate Valeant Pharmaceuticals Intl's stock price to reach C$23.33 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.
Who are some of Valeant Pharmaceuticals Intl's key competitors?
Some companies that are related to Valeant Pharmaceuticals Intl include Smith & Nephew plc (SN), Omnicare (OCR), NMC Health PLC (NMC), Health Net (HNT), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Patheon NV (PTHN), Catalent (CTLT), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV), Ligand Pharmaceuticals (LGND), Enerplus Corp (ERF), Hikma Pharmaceuticals Plc (HIK), Axovant Sciences Ltd (AXON), BTG plc (BTG), Select Medical Holdings (SEM) and Hutchison China MediTech Limited (HCM).
Who are Valeant Pharmaceuticals Intl's key executives?
Valeant Pharmaceuticals Intl's management team includes the folowing people:
- Joseph C. Papa, Chairman of the Board, Chief Executive Officer
- Paul S. Herendeen, Chief Financial Officer, Executive Vice President
- Christina Ackermann, Executive Vice President, General Counsel
- Thomas J. Appio, Executive Vice President, Company Group Chairman, International
- William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
- Thomas W. Ross Sr, Lead Independent Director
- Richard U. DeSchutter, Independent Director
- Fredric N. Eshelman Pharm.D., Ph.D., Independent Director
- D. Robert Hale, Independent Director
- Argeris N. Karabelas Ph.D., Independent Director
How do I buy Valeant Pharmaceuticals Intl stock?
Shares of Valeant Pharmaceuticals Intl and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Valeant Pharmaceuticals Intl's stock price today?
One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately C$16.90.
MarketBeat Community Rating for Valeant Pharmaceuticals Intl (TSE VRX)MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Valeant Pharmaceuticals Intl (TSE:VRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.20) |
| Consensus Price Target: | C$23.33 |
Analysts' Ratings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 7/12/2017 | TD Securities | Boost Price Target | Hold | C$26.00 |  |
| 6/29/2017 | Cantor Fitzgerald | Reiterated Rating | Overweight | | |
| 6/19/2017 | Royal Bank of Canada | Reiterated Rating | Sector Perform | C$25.00 | |
| 5/10/2017 | Scotiabank | Boost Price Target | Sector Perform | C$19.00 | |
| 12/15/2016 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | | |
| 11/19/2015 | Citigroup Inc. | Reiterated Rating | Overweight | | |
| 11/2/2015 | Goldman Sachs Group, Inc. (The) | Downgrade | Buy -> Neutral | | |
(Data available from 9/20/2015 forward)
Earnings History for Valeant Pharmaceuticals Intl (TSE:VRX)Earnings History by Quarter for Valeant Pharmaceuticals Intl (TSE VRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2017 | | | | | | | | |
| 5/8/2014 | | C$1.83 | C$1.90 | | C$2.05 billion | View | N/A | |
| 8/7/2013 | 2Q13 | | C$0.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Valeant Pharmaceuticals Intl (TSE:VRX)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2017 | 1 | $1.05 | $1.05 | $1.05 |
| Q4 2017 | 1 | $1.01 | $1.01 | $1.01 |
(Data provided by Zacks Investment Research)
Dividend History for Valeant Pharmaceuticals Intl (TSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals Intl (TSE:VRX)Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/21/2017 | Schutter Richard Urbain De | Director | Buy | 4,900 | C$14.35 | C$70,315.00 | |
| 8/9/2017 | John Paulson | Director | Sell | 24,700 | C$14.66 | C$362,102.00 | |
| 5/11/2017 | Schutter Richard Urbain De | Director | Buy | 20,000 | C$13.90 | C$278,000.00 | |
| 3/15/2017 | Schutter Richard Urbain De | Director | Buy | 10,000 | C$10.80 | C$108,000.00 | |
| 11/5/2015 | J. Michael Pearson | Director | Sell | 350,000 | C$0.00 | C$0.00 | |
| 10/21/2015 | Ron Farmer | Director | Buy | 1,000 | C$193.00 | C$193,000.00 | |
| 5/26/2015 | Whitaker Anne | Insider | Buy | 2,500 | C$234.00 | C$585,000.00 | |
| 5/4/2015 | Robert Roswell Chai-Onn | Insider | Sell | 90,938 | C$222.54 | C$20,237,433.46 | |
(Data available from 1/1/2013 forward)
Headline Trends for Valeant Pharmaceuticals Intl (TSE:VRX)
Latest Headlines for Valeant Pharmaceuticals Intl (TSE:VRX)
| Source: |
|
| Date | Headline |
|---|
 | GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors - Benzinga
www.benzinga.com - September 19 at 3:27 PM |
| What You Should Know About The Drug Approval Valeant Could Receive This Week - Benzinga
www.benzinga.com - September 19 at 9:26 AM |
 | Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 7:54 AM |
| Valeant Commits $200,000 to Support Hurricane Relief Efforts
finance.yahoo.com - September 15 at 11:15 AM |
 | Has Valeant Run Out Of Catalysts? - Seeking Alpha
seekingalpha.com - September 13 at 11:07 AM |
 | Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy - Investorplace.com
investorplace.com - September 13 at 11:07 AM |
 | Valeant Pharmaceuticals International Breaks Above 200-Day Moving Average - Bullish for VRX
www.nasdaq.com - September 12 at 12:01 PM |
 | Valeant Pharmaceuticals Intl Inc (VRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 10 at 2:42 AM |
| Follow the Crucial '$20 Level Rule' When Trading Stocks
finance.yahoo.com - September 9 at 9:48 AM |
| Valeant: This just got unreasonable - Seeking Alpha
seekingalpha.com - September 6 at 10:04 AM |
| Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
finance.yahoo.com - September 6 at 10:04 AM |
| Valeant To Participate At The Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 6 at 10:04 AM |
| Daily Coverage on Healthcare Stocks, Valeant Pharma International, Nuvo Pharma, Knight Therapeutics, and Acerus Pharma
finance.yahoo.com - September 6 at 10:04 AM |
| Valeant: A Clear Sell - Seeking Alpha
seekingalpha.com - September 3 at 8:04 AM |
| Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Be Just Fine ... - Investorplace.com
investorplace.com - September 3 at 8:04 AM |
 | Better Turnaround Play: Bombardier, Inc. vs. Valeant Pharmaceuticals Intl Inc.
www.msn.com - September 2 at 10:18 AM |
| Wilmington company sues former partner following work for Salix, Valeant
finance.yahoo.com - September 1 at 10:54 AM |
| The Simple Reason I Won't Buy Intrexon
finance.yahoo.com - September 1 at 10:54 AM |
| Valeant: Headline Risk Vs. Fundamentals - Seeking Alpha
seekingalpha.com - August 30 at 10:56 AM |
| Valeant Pharmaceuticals: Weakness, Weakness Everywhere?
finance.yahoo.com - August 30 at 10:56 AM |
| Why Did Valeant Pharmaceuticals (VRX) Stock Fall Today?
finance.yahoo.com - August 30 at 10:56 AM |
| Valeant: No Fundamental Reasons for Today's Selloff?
finance.yahoo.com - August 30 at 10:56 AM |
| Valeant Pharmaceuticals Intl Inc (VRX) Stock Falls on New Legal Battle - Investorplace.com
investorplace.com - August 29 at 9:31 AM |
| Is the Valeant Pharmaceuticals Intl Inc (VRX) Debt Situation Overblown? - Investorplace.com
investorplace.com - August 25 at 3:34 PM |
| Here's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy)
finance.yahoo.com - August 25 at 12:26 PM |
| Valeant’s Latest Legal Threat Could Be Especially Costly
finance.yahoo.com - August 25 at 12:26 PM |
| Valeant: The Long or Short of It
finance.yahoo.com - August 25 at 12:26 PM |
| Valeant's Legal Bills Are Piling Up Following Latest Securities Fraud Lawsuit
finance.yahoo.com - August 25 at 12:26 PM |
| Schutter Richard Urbain De Purchases 4,900 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
www.americanbankingnews.com - August 24 at 10:34 PM |
| Valeant Looks Good Post-Q2 - Seeking Alpha
seekingalpha.com - August 23 at 11:45 PM |
| What's The FDA Saying About Valeant (NYSE: VRX)'s ... - Benzinga - Benzinga
www.benzinga.com - August 23 at 1:41 PM |
| Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today - Investorplace.com
investorplace.com - August 19 at 8:54 AM |
| Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Gamble You Can Win - Investorplace.com
investorplace.com - August 19 at 8:54 AM |
 | Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility - PR Newswire (press release)
www.prnewswire.com - August 17 at 9:09 AM |
| The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak - Investorplace.com
investorplace.com - August 17 at 9:09 AM |
| ETFs with exposure to Valeant Pharmaceuticals International, Inc. : August 16, 2017
finance.yahoo.com - August 17 at 9:09 AM |
| Valeant Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - August 17 at 9:09 AM |
| Valeant’s Tampa manufacturing plant on track for a better bill of health
finance.yahoo.com - August 17 at 9:09 AM |
| Valeant Pharmaceuticals Intl Inc (VRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 16 at 3:10 PM |
 | Long-Term Investors: Buy the Dip With Valeant Pharmaceuticals Intl Inc. - The Motley Fool Canada
www.fool.ca - August 11 at 3:56 PM |
| Valeant: Earnings Expose Problem - Seeking Alpha
seekingalpha.com - August 11 at 3:56 PM |
| Q3 2017 Earnings Forecast for Valeant Pharmaceuticals Intl Inc Issued By Jefferies Group (TSE:VRX)
www.americanbankingnews.com - August 11 at 8:12 AM |
| Edited Transcript of VRX.TO earnings conference call or presentation 8-Aug-17 12:00pm GMT
finance.yahoo.com - August 10 at 8:44 PM |
| Valeant Pharmaceutical Intl Inc. Is Back on the Growth Track: Time to Buy?
www.fool.ca - August 10 at 3:42 PM |
| Valeant: There's No Denying It - Seeking Alpha
seekingalpha.com - August 10 at 3:42 PM |
| Valeant Pharmaceuticals International, Inc. :VRX-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 3:42 PM |
| Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View - Nasdaq
www.nasdaq.com - August 10 at 9:31 AM |
| Valeant: Much More Upside Remains, Despite Messy Quarter - Seeking Alpha
seekingalpha.com - August 10 at 9:31 AM |
| Valeant Pharmaceuticals: A Lesson In Value Traps - Seeking Alpha
seekingalpha.com - August 10 at 9:31 AM |
| 5 Reasons Valeant's Situation Could Get Worse
finance.yahoo.com - August 10 at 9:31 AM |
Valeant Pharmaceuticals Intl (VRX) Chart for Wednesday, September, 20, 2017
